Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vanillin in the preparation of medicines for treating/preventing bone metabolic diseases

A technology of vanillin and bone metabolism, applied in the field of biomedicine

Active Publication Date: 2021-04-20
ARMY MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report or application of vanillin in the skeletal system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vanillin in the preparation of medicines for treating/preventing bone metabolic diseases
  • Application of vanillin in the preparation of medicines for treating/preventing bone metabolic diseases
  • Application of vanillin in the preparation of medicines for treating/preventing bone metabolic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1. Effect of vanillin concentration on inhibiting the proliferation of osteoclast precursors

[0032] Divide RAW264.7 cells to 1 x 10 3Cells / well were inoculated into 96-well plates, and the medium was discarded after the cells were full. The medium was composed of: DMEM high-glucose medium + 10% fetal bovine serum + 1% double antibody (penicillin) at the final concentration Add 0 mM, 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM, 4 mM vanillin to each well plate containing fresh medium (the concentration of DMSO is controlled at less than 0.1%) to interfere with RAW264.7 cells . After culturing for 24h, 48h and 72h respectively, the cell viability was detected by the CCK-8 method, and the effect of the proliferation of RAW264.7 cells under the intervention of vanillin was observed. A step-by-step experimental investigation.

[0033] The result is as figure 1 shown, where figure 1 A is the chemical formula of vanillin; figure 1 In the middle, B-D are th...

Embodiment 2

[0035] Example 2. Vanillin concentration-dependent reduction in RANKL-induced osteoclast formation (TRAP positive cells)

[0036] Taking no RANKL induction as the control group, RANKL induction and the effect of different vanillin concentrations as the experimental group, the groups were grouped according to the following conditions:

[0037] Group 1: no RANKL induction, 0mM vanillin control group;

[0038] Group 2: RANKL (50ng / mL) induction, 0mM vanillin experimental group;

[0039] Group 3: RANKL (50ng / mL) induction, 0.25mM vanillin experimental group;

[0040] Group 4: RANKL (50ng / mL) induction, 0.5mM vanillin experimental group;

[0041] Group 5: RANKL (50ng / mL) induction, 1mM vanillin experimental group;

[0042] Group 6: RANKL (50ng / mL) induction, 2mM vanillin experimental group.

[0043] Divide RAW264.7 cells into 2 x 10 3 Cells / well were inoculated into 96-well plates, and the medium was discarded after the cells were full. The medium was composed of: DMEM high-gl...

Embodiment 3

[0045] Example 3. Vanillin concentration-dependent reduction of RANKL-induced multinucleated mature osteoclast formation

[0046] Taking no RANKL induction as the control group, RANKL induction and the effect of different vanillin concentrations as the experimental group, the groups were grouped according to the following conditions:

[0047] Group 1: no RANKL induction, 0mM vanillin control group;

[0048] Group 2: RANKL (50ng / mL) induction, 0mM vanillin experimental group;

[0049] Group 3: RANKL (50ng / mL) induction, 0.25mM vanillin experimental group;

[0050] Group 4: RANKL (50ng / mL) induction, 0.5mM vanillin experimental group;

[0051] Group 5: RANKL (50ng / mL) induction, 1mM vanillin experimental group;

[0052] Group 6: RANKL (50ng / mL) induction, 2mM vanillin experimental group.

[0053] The RAW264.7 passaged cells were continued to be cultured, and after the cell density at the bottom of the flask reached 90%, the cells were scraped with a cell scraper to collect t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of vanillin in the preparation of medicines for treating / preventing bone metabolism diseases, through which vanillin inhibits the proliferation of osteoclasts, the formation of multinucleated mature osteoclasts and the osteophagic ability of osteoclasts, and promotes mature osteoclasts Apoptosis regulates osteoclast differentiation, fusion, maturation genes and related genes of apoptosis, which can maintain bone homeostasis, prevent bone loss, maintain bone density, and provide a therapeutic / preventive solution for diseases caused by osteoclast activity. new drug.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the application of vanillin in the preparation of medicines for treating / preventing bone metabolic diseases. Background technique [0002] Unlike the rest of the osteocytes in the bone, osteoclasts (Osteoclast, OC) are derived from the monocyte / macrophage cell line differentiated from hematopoietic stem cells (HSCs). The particularity of its source determines the multi-faceted role of osteoclasts in the skeletal system. In addition to its main function, which is bone resorption, osteoclasts are involved in angiogenesis, osteoimmunology and hematopoiesis. It plays an important role in the formation of the microenvironment (hematpoietic niche). However, the most important and most studied function of osteoclasts is their bone resorption capacity and their interaction with the rest of osteocytes, mainly osteoblasts. Bone resorption by osteoclasts and bone regeneration by osteoblasts are t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/11A61P19/10A61P19/08
CPCA61K31/11
Inventor 陈玥琦董世武窦策
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com